肿瘤特异性蛋白70用于乳腺肿瘤良恶性鉴别

摘要

目的:探讨肿瘤特异性蛋白70(tumor specific protein 70,SP70)在乳腺肿瘤组织及血液中的表达情况及其对乳腺肿瘤良恶性鉴别的意义.方法:乳腺肿瘤患者125例(乳腺癌65例、良性病变60例),免疫组化法检测切片中SP70的表达.ELISA检测120例乳腺肿瘤患者(58例乳腺癌、62例乳腺良性疾病)和60例健康体检者血清中SP70蛋白的水平.结果:SP70在乳腺癌组织中的表达阳性率(55.38％)高于乳腺良性病变(15.00％),差异有统计学意义(x2=23.846,P＜0.001).乳腺癌患者血清中SP70的水平显著高于乳腺良性疾病患者和健康对照,差异有统计学意义(F=11.884,P＜0.001).SP70在血清中的敏感性高于CA153(53.45％ vs.44.82％),且血清中SP70和CA153的表达无显著相关性(r=0.132,P=0.324),两者联合能够明显提高检测敏感性(84.38％).结论:检测乳腺肿瘤组织和血液中SP70的表达对其良恶性的鉴别有重要临床价值.%Objective:To investigate the expression of tumor specific protein 70 (SP70) in breast cancer tissues and blood to evaluate whether SP70 could differentiate the benign breast tumor and malignant breast tumor.Methods:The SP70 expressions of paraffin sections in the tissues of 65 malignant breast tumors and 60 benign breast tumors were studied by immunohistochemistry(IHC) technique.The levels of SP70 in the serum of 58 malignant breast tumors,62 benign breast tumors and 60 healthy subjects were studied by enzyme-linked immuno sorbent assay(ELISA).Results:The expression positive rate of SP70 was 55.38％ in the tissues of malignant breast tumors,whereas,only 15.00％ in benign breast tumors.The difference was statistically significant (x2=23.846,P＜0.001).The serum SP70 level of patients with malignant breast tumors was significantly higher than that in patients with benign breast tumors and healthy controls(F=1 1.884,P＜0.001).The sensitivity of serum SP70 for diagnosis of malignant breast tumors was significantly higher than that of serum CA153 (53.45％ vs.44.82％),a significant association between serum SP70 and serum CA153 had not been found (r=0.132,P=0.324).The combine of serum SP70 and serum CA153 could significantly improve the sensitivity (84.38％).Conclusion:SP70 may be used to differentiate diagnosis of malignant breast tumors and benign breast diseases.